MAPS Annual Report
To sustain itself in its current form for more than several years, MAPS needs to try to
raise an endowment of $600,000. An increase in membership from 1,850 to 2,500 would
also help to raise additional funds for organizational expenses. This Annual Report is an
invitation for dialogue; MAPS members are encouraged to review it and share with the staff
any comments, suggestions or questions that they would like to offer. We will do our best
to be worthy of your renewed support.
In partnership with its members, MAPS continues in its efforts to develop socially
sanctioned contexts for the time-honored potential of psychedelics and marijuana to
facilitate healing, inspiration, creativity and spiritual growth. Current MAPS members are
an unusual group of people willing to support efforts to make this vision of the beneficial
uses of psychedelics and marijuana into a reality. MAPS is deeply grateful for the past
generosity of its members.
Fiscal Year June 1, 1998 - May 31, 1999 (FY 98-99) was another year of
accomplishments. More than twice as much money was devoted to educational projects than
research projects, due in part to continued struggles to obtain permission for research.
was more evenly divided between educational and research efforts, primarily because
resolve and overcome bureaucratic obstacles to research requires more time and effort
MAPS' efforts on behalf of research bore fruit this summer - after the close of MAPS'
98-99 - with three FDA decisions which we reported in the last Bulletin (Vol. IX No. 3).
FDA approved MAPS' application to have marijuana designated an Orphan Drug for AIDS
wasting. Second, the FDA approved Dr. Ethan Russo's MAPS-supported marijuana/migraine
protocol. Finally, the FDA decided to permit Dr. Charles Grob to move forward with a
supported study of MDMA in cancer patients, with the exact protocol design still to be
Financially, total expenditures of $280,194 in MAPS' FY 98-99 were essentially the
as the $288,548 spent in FY 97-98, permitting MAPS to continue to support a wide variety
projects. Income was substantially greater in FY 98-99, rising to $308,743 from $227,637,
primarily due to an increase in large grants restricted to specific projects. MAPS'
continues to grow gradually and reached 1850 with our target of 2500 members still to be
MAPS' net assets were $351,701 as of May 31, 1999. Of this amount, $80,000 is
restricted to specific research and educational projects. These sums need to be subtracted
assets when considering MAPS' unrestricted funds available for new projects or
expenses. MAPS' goal as a non-profit organization is not to increase its net assets, but to
its mission. Nevetheless, having some net assets gives MAPS the ability to commit to
priority projects and gives a measure of stability in the face of fluctuating contributions
As in previous years, MAPS' statement of income and expenses is published in the
along with a detailed explanation of the individual expense items. In this way, MAPS
can review exactly how their donations were allocated and what expenses were incurred.
report is an invitation for dialogue; MAPS members are encouraged to review it and share
the staff any comments, suggestions or questions that they would like to offer. MAPS will
to flourish only to the extent that the expenditures it makes correspond closely to the
its members. As a result, we publish this detailed accounting and seek your input.
MAPS supports the efforts of researchers around the world to study the beneficial uses,
mechanisms of action and risk profiles of psychedelic drugs. In FY 98-99, MAPS allocated
support protocol design for two MDMA psychotherapy projects, one in the United States
another in Israel. MAPS also supported expenses involved in conducting an MDMA safety
in Switzerland, two follow-up studies to pioneering LSD research, an LSD psychotherapy
design effort in the United States, a project to study the effect of the non-medical use of
psychedelics within a family context, a ketamine psychotherapy project in heroin addicts
conducted in Russia, and a study of meditation combined with Salvia divinorum, conducted
MAPS staff spent substantial time, but no money, in preliminary development of
research protocols, some of which will be supported by MAPS if and when they become
The highest priority of these studies in development is the MDMA/PTSD study being
by Ph.D. student, Jose Carlos Bouso, in Madrid, Spain.
MAPS allocated funds to a marijuana analysis project in the United States investigating
potency of marijuana used in medical marijuana buyers clubs
(MAPS Bulletin Vol IX No.
MAPS also devoted a great deal of staff time, but no funding, to its successful effort to
designate marijuana an Orphan Drug for AIDS wasting syndrome, and to Dr. Ethan Russo's
to obtain FDA permission for a marijuana/migraine study. Dr. Donald Abrams' study of
of marijuana in HIV patients taking protease inhibitors - for which MAPS and Dr. Abrams
for five and a half years to obtain final permission and funding - treated 46 subjects out
of a total
of 64 (page 40, this issue).
MAPS devoted substantial resources to the publication of the quarterly MAPS Bulletin.
MAPS continued to market and started to pay royalties on The Secret Chief, the first book
published. MAPS made a donation in support of the re-publication of Shivitti: A Vision by
concentration camp survivor on his experiences undergoing LSD psychotherapy. MAPS also
helped support the writing of three new books, on DMT research, on medical marijuana,
the penalties imposed on non-medical users of psychedelics and other drugs. MAPS
disseminate information on MAPS' Internet web site. MAPS focused resources on the
and posting of a searchable version of the Sandoz bibliography of scientific papers on LSD
psilocybin, started a project creating an electronic annotated bibliography of current
papers published in peer-review journals, and supported the MAPS Forum, a moderated e-
discussion group. MAPS allocated funds to two conferences, a Psychedelic Elders
took place in the United States and a MAPS-sponsored conference on clinical research with
MDMA and MDE that took place in Israel. MAPS also undertook a membership drive that
the mailing of over 50,000 brochures about MAPS and psychedelic research. MAPS staff
significant time but no money responding to numerous media requests for information,
replying to members' questions.
MAPS' expenditures in FY 98-99 amounted to $280,194. This compares to $288,548 in
FY 97-98, $255,746 in FY 96-97, $185,797 in FY 95-96, and $133,153 in FY 94-95.
MAPS' income in FY 98-99 was $308,743. This compares to $227,637 in FY 97-98, an
astonishing $558,683 in FY 96-97 (due primarily to the bequest from Eric Bass, which
MAPS to substantially enlarge its range of projects), $200,182 in FY 95-96 and $107,184
At the close of FY 98-99, MAPS had assets of $351,701, $80,000 of which were
to specific projects.
MAPS has yet to call on a pledge of $58,000 from a family Foundation for Dr.
Grob's proposed research project evaluating the use of MDMA in terminal cancer patients.
grant will be allocated only after all the required regulatory approvals have been
hopefully by the spring of 2000.
MAPS' financial picture in FY 98-99 is solid, though some long-term issues need to be
addressed if MAPS can continue into the future as an organization providing the current
services and project support. The fundamental issue is that MAPS' organizational expenses
unrestricted income. This is sustainable for the next several years since MAPS has a
the form of assets, primarily the remaining portion of Eric Bass' bequest. To sustain itself
current form for more than several years, MAPS needs to try to raise an endowment of
An increase in membership from 1,850 to 2,500 would also help to raise additional funds
organizational expenses. I expect that continued success in obtaining permission for
beneficial uses of psychedelics and marijuana, as well as growth in the quality, range and
MAPS' educational projects, will generate increased enthusiasm and support for MAPS
hope and trust that this enthusiasm and support will translate both into new members and
donations for a permanent endowment.
Compared to the costs of clinical trials into the risks and benefits of psychedelic drugs
marijuana, MAPS resources are insufficient. As a result, MAPS focuses on supporting pilot
that, if promising results are generated, can be used to generate larger donations for full-
trials. In other words, MAPS provides initial risk capital for projects in the early stages
development. Some of these projects will succeed in producing promising results and some
not, as is the case for all scientific research. The key to maximizing the value of the
MAPS receives from members is for MAPS to make sure that valuable lessons are gathered
the projects that do not succeed, and to work as hard as possible to secure additional
projects that do warrant continued investigation. In the effort to support larger scale
will continue to develop a working relationship with the Heffter Research Institute (HRI)
is also committed to supporting scientifically rigorous research projects. MAPS will also
to larger, more established foundations and government funding sources when
possible support seem within the realm of possibility, however slight. MAPS can itself
clinical trials only if it receives donations on a scale which it has yet to obtain.
MAPS' income in FY 98-99 was $308,743. Of this amount, $70,371 came from
Foundation grants, with these foundations being primarily family foundations. Donations
individuals amounted to $197,675. Of this amount, donations from the 9 individual donors
contributed $2,000 or more amounted to $90,862. MAPS' approximately 1800 other
contributed a total of $106,813 for an average donation of $59, as compared to an average
donation of $68 in FY 98-99. Investment income (dividends, interest and capital gains)
$24,194. Sales of the Bulletin and books generated $16,502.
The foundation grants came from the following sources: Promind Foundation
Bob Wallace - $39,371; S. Family Foundation - $10,000, Institute of Noetic Sciences -
Tarcher Family Foundation - $5,000; PLACE Foundation - $5,000; Zimmer Foundation -
Heffter Research Institute - $2,000, Odyssey Foundation - $2,000.
The largest donations of $2,000 or more given by individuals were from the following
Tim Butcher - $21,500, Ami Shinitzky - $18,500,
Robert Barnhart - $12,000, John Gilmore - $10,351, Melisa Richardson - $10,000, Andrew
- $9,511, Anonymous - $5,000, Anonymous - $2,000.
From an organizational development standpoint, the donations of less than $2,000 from
MAPS' approximately 1800 members form the core recurring resource. In FY 98-99, these
donations totalled $106,813. In order to increase the stability of MAPS as an organization,
necessary to increase the number of members who contribute regular membership
MAPS added 250 members in this last fiscal year. MAPS conducted a test of a new bulk
appeal but the appeal was of limited success. This suggests once again the value of word of
as a tool for organizational development, and leads me to urge any MAPS readers who are
reviewing this document in detail to mention MAPS to their friends.
Total expenditures for FY 98-99 amounted to $280.194. The expenditures have been
divided into four categories; research, education, staff and office. In FY 98-99, MAPS
$42,318 to research, $107,119 to education, $116,459 to staff and $14,298 to office. By
comparison, in FY 97-98 MAPS allocated $54,209 to research, $119,982 to education,
to staff and $14,132 to office. MAPS' individual expense items are discussed below in
MDMA Cancer Patient
Study -United States
Charles Grob, M.D. is the lead investigator for the proposed study into the use of MDMA
the treatment of psychological distress in terminal cancer patients. MAPS allocated
$4,460 to this
project. Of that sum, $1,250 went for expenses involved in reviewing the scientific
submission to FDA. A neurotoxicity review was started by Matt Baggott and a review of the
of MDMA on kidney function was started by John Podraza. The remaining funds were
protocol development work, which included expenses involved in assisting Dr. Grob to
latest data on MDMA neurotoxicity at scientific conferences in London and Washington,
working to support efforts to initiate MDMA psychotherapy research in cancer patients
MAPS was founded in 1986, I think we will finally see FDA approval of such a study
before I will
be writing next year's annual report.
MDMA PTSD Study -
In FY 97-98, MAPS began the process of trying to catalyze an MDMA/PTSD study in
Israel, in association with Dr. Moshe Kotler, Chairman of the Department of Psychiatry,
Mental Health Center, Ben-Gurion University of the Negev. In FY 98-99, MAPS allocated
to this project. These costs primarily involved informing Dr. Kotler and his co-
Adam Darnell, about MDMA neurotoxicity by bringing them to scientific conferences. Both
attended a conference about MDMA neurotoxicity in London, at which Drs. Grob and Greer
joined them. Dr. Darnell (and myself and Dr. Grob) attended a neurotoxicity conference in
Washington, D.C. I felt it was essential that Drs. Kotler and Darnell be exposed to the
of scientific information about the risks of MDMA. In that way, they would be in the best
to make a fully informed decision about how to proceed with MAPS' proposed study.
after hearing the latest information about MDMA neurotoxicity, they felt that the
was such that proceeding with the study was still an appropriate course of action.
As reported below in the educational section, expenditures involved in bringing MDMA
researchers to Israel to present their data to Israeli health authorities have been allocated
Israel MDMA conference. As I reported last year, a donation of $12,500 to cover the initial
protocol design process of the MDMA/PTSD study was made by MAPS members (my
parents) but was routed not through MAPS but given directly to Ben-Gurion University for
restricted use for the study.
PET Study -
MAPS donated $6,000 to lend partial support to a crucial study conducted by Dr. Franz
Vollenweider, University of Zuerich, designed to use PET scans to determine whether a
dose of MDMA administered to MDMA-naive subjects would result in any detectable
long-term reductions in serotonin transporter reupdate sites. Dr. Vollenweider and his
team, and Drs. George Ricaurte and Una McCann and their team at Johns Hopkins
the only scientists in the world using PET scans to measure serotonin reuptake sites in
users. The primary difference between the approaches of the two teams is that Dr.
tests the effect of a single standard-size dose in MDMA-naive subjects, producing data
directly relevant for determining the risk to subjects from participating in clinical
Ricaurte and McCann test polydrug users with a history of hundreds of exposures to large
MDMA, among a wide range of other drugs, and compares their results to a supposedly
control group, generating data that may bear on the risk of heavy recreational use of
Preliminary data from Dr. Vollenweider's study suggests that a single dose of 1.5
may not produce any measurable reductions in serotonin transporter reuptake sites. This
needs to be confirmed in larger numbers of subjects and then submitted for publication
subjected to the peer-review process. The results of this study, if they hold up after
subjects and higher doses are evaluated, can play an important role in reassuring
review bodies that MDMA research can be conducted without undue risk of neurotoxicity
Addiction Study -
In FY 98-99, MAPS donated $8,857 to Dr. Evgeny Krupitsky for the third year of a
year study of the use of a single session of ketamine-assisted psychotherapy in the
heroin addiction. The study is taking place in Russia at the Leningrad Regional Center for
Treatment of Addiction. MAPS' support for the project was provided by a restricted grant
In addition, MAPS assisted Dr. Krupitsky in the protocol design process. HRI has also
donated $5,000 a year for three years to Dr. Krupitsky for this study. The joint
sponsorship of Dr.
Krupitsky's study by HRI and MAPS is an example of the increasingly collaborative nature
relationship between these two organizations, both of which are working to support
All subjects have been tested and the results at the six-month follow-up period have
analyzed and published in this issue of the Bulletin (pp. 21). Additional follow-ups at
intervals will be conducted and submitted for publication to peer-reviewed journals. Dr.
Krupitsky's study has yielded promising and provocative results. Dr. Krupitsky and
begun discussions about the design and funding of additional studies evaluating whether
sessions with ketamine-assisted psychotherapy will increase rates of abstinence and/or
of drug use patterns beyond that achieved from a single session.
Follow-Up to Dr.
Janiger's LSD Research
MAPS spent $11,276 in FY 98-99 for the historic follow-up study to LSD research that
was conducted from 1954-1962 by Dr. Oscar Janiger. Follow-up interviews with over 40
were conducted by Kate Chapman. A detailed report on the findings of this study appeared
recent MAPS Bulletin (Vol IX No. 1), and media reports appeared in the Utne Reader, the
Weekly, and other newspapers around the country. The results of this study provided
evidence that LSD research could be conducted safely and that a significant fraction of
this experiment reported that their LSD experiences had lasting benefits. The Janiger
study may mark the end in a series of long-term follow-ups to early psychedelic research
that MAPS has sponsored (see pp. 10 this issue). The data gathered from these follow-up
provide sufficient evidence of safety and efficacy to justify the initiation of new studies
psychedelics are administered to patients.
Follow-up to Dr.
Bastiaans' LSD Therapy -
MAPS pledged $5,000 and in FY 98-99 donated the first $2,500 to a follow-up study of
Dr. Bastiaans' patients treated for PTSD with LSD-assisted psychotherapy. Some of these
were concentration camp survivors. The results of this study were published in MAPS (Vol
2). This study provides anecdotal information suggesting that further research into the
psychedelically-assisted psychotherapy in patients with PTSD should be conducted. MAPS
working on protocol design and has pledged funding for two studies of this sort, one in
one in Spain, both using MDMA in treatment-resistent PTSD patients.
Richard Yensen, Ph.D. and Donna Dryer, M.D., have been working for many years to
FDA permission to administer LSD to humans within a therapeutic context. Drs. Yensen
are now engaged in the process of redesigning a protocol for the use of LSD in the
cancer patients. MAPS allocated $57 for the purchase of a book on outcome measures
evaluating psychological changes in cancer patients.
MAPS donated $540 to Adele Getty for assistance in protocol design for an interview
intended to gather information from families where the use of psychedelics is openly
(MAPS Bulletin Vol IX No. 2). This study may shed some light on whether parental
acknowledgment of the benefits of the responsible use of psychedelics "sends the wrong
or acts as a protection against drug abuse in adolescents and young adults.
MAPS donated $1,500 to a double-blind study examining the use of low doses of Salvia
divinorum as an aid to meditation (MAPS Bulletin Vol. IX No. 2). Though MAPS primarily
its resources on the medical aspects of psychedelics and marijuana, this study
more traditional use of psychedelics as aids to spiritual practice.
MAPS and CA-NORML cosponsored a study into the potency of various samples of
marijuana sold at medical marijuana buyers clubs around the country. The data support
contention that the potency and quality of the marijuana supplied by NIDA to FDA-
research protocols is significantly inferior to the marijuana preferred by patients (MAPS
Vol. IX, No. 3).
MAPS allocated $107,119 to educational projects in FY 98-99. The educational
of MAPS' activity includes the printing and mailing of the MAPS Bulletin, the writing,
and marketing of books, the development of information and searchable databases
available on the
MAPS web site, organizing and supporting conferences, conducting membership drives,
associated costs for copies, phones, internet connection, postage, advertisements, books
and informational materials.
In FY 98-99, as in FY 97-98, educational projects represented the largest category of
expenditure. This is due in part to the lengthy and difficult process of securing
clinical research, a process which I expect will be less problematic in the future. MAPS'
educational projects is also due to our growing recognition that MAPS' educational
an important adjunct to research, and that approval for research depends upon public
such research and the minimization of possibly tragic negative experiences in non-
of psychedelics. The educational functions of MAPS thus act as a necessary component of a
complete strategy that recognizes the need for the dissemination of accurate, balanced
in support of the education and associated harm-reduction in non-medical users of
and the education of the general public on research results from psychedelic and
The MAPS Bulletin is the major educational project of MAPS. MAPS spent $23,496
printing the Bulletin, the envelopes, and the enclosures we sometimes include in the
The mailing of the Bulletin also consumed a substantial fraction of the $8,760 spent on
The Bulletin continues to take a great deal of staff time as well as the donated time and
talent of a
graphic designer who gives the Bulletin its professional look. The annual per-member
costs of the
Bulletin are quite high, in excess of $10 per member (subtracting for the copies of the
on newstands and sent for free to key scientists, government officials and media). This
not count staff time to produce the Bulletin. We feel that this expenditure in
our members is well worth the money. Furthermore, the Bulletin is also posted on the
page and is available to a much larger group of people. We welcome comments from
concerning ways to improve the Bulletin.
The Sandoz on-line psychedelic bibliography is a shared project between MAPS, HRI
the Albert Hofmann Foundation. MAPS spent a total of $12,696 in FY 98-99 on this
funds donated by Bob Wallace through his Promind Foundation. The goal of this project is
digitize the Sandoz bibliography of all scientific papers published about LSD and
their initial synthesis up to 1980, when Sandoz stopped collecting research papers. The
psychedelic bibliography is now a very powerful tool and preserves early LSD and
research in an easily accessible form for future generations of students and researchers.
On-Line Summary of
In a related project, MAPS spent $1,250 to gather, post in the searchable data base, and
comment on all new scientific papers about the use of psychedelics in humans that are
in peer-reviewed journals, all clinical studies in humans with marijuana, and results of
important psychedelic-related animal studies. MAPS has hired Matt Baggott to implement
project, with funding provided by Bob Wallace's Promind Foundation.
MAPS spent $3,450 on the Forum in FY 97-98. MAPS' on-line discussion group is
moderated by Jon Frederick, a neurosciences Ph.D. candidate at the University of
Knoxville. Jon has done an excellent job and has built participation to over 1500 people.
receives a monthly $300 stipend for his services, and MAPS pays for his internet
Forum is an excellent method for MAPS to communicate with participants in the Forum,
whom are members but many are not, and for participants to communicate with each other.
continues to believe that it is best to give out information for free, hoping that many will
and some will become members to help cover the costs of the service. To subscribe, send a
to email@example.com with subscribe maps_forum youre-mailaddress in the body of
MAPS is donating $2,000 a month for one year to Dr. Rick Strassman to enable him to
have time to write a book on his experiences conducting DMT and psilocybin research.
this project comes from a grant from Robert Barnhart. This book will be published by
New Edition of
Shivitti: A Vision
MAPS donated $1,500 toward the re-publication by Gateways Books of Shivitti- A
by Ka-Tzetnik 135633. This book is about the LSD-assisted psychotherapy that Ka-
135633 underwent to help him deal with the long-term emotional consequences of having
in a Nazi concentration camp. This book is available from
MAPS helped underwrite the costs of publicizing this book because it is an excellent
account of the use of psychedelic-assisted psychotherapy in the treatment of PTSD, a use
MAPS is trying to study in the context of MDMA/PTSD research projects in Israel and
MAPS donated $2,500 as a final contribution to Chris Conrad and Mikki Norris for
work in researching Hemp for Health: The Facts on Medical Marijuana (by Conrad) and
Lives: Portraits from America's Drug War (by Norris, Conrad and Virginia Resner). MAPS
restricted grant of $2,500 from the Zimmer Family Foundation for these projects. This
be ordered through local bookstores.
MAPS spent $2,280 in FY 98-99 marketing The Secret Chief by Myron Stolaroff. The
is a series of interviews with a pioneer of the underground psychedelic psychotherapy
MAPS staff member Carla Higdon worked on the promotional efforts. If you haven't already
purchased a copy, you can do so through the MAPS web site, by calling the MAPS office or
ordering through your local book store. Only a few copies of the special limited edition of
signed copies are still available at $250 each (signed by Albert Hofmann, Stan Grof, Ann
Sasha Shulgin, and Myron Stolaroff). MAPS also had the pleasure of paying Myron $1,914
royalty payments for writing The Secret Chief . While this is not a large amount of money,
Myron didn't have to write the book only for love. MAPS' costs for publishing and
Secret Chief were funded by a $10,000 grant from Bob Wallace, through the Promind
(donated prior to FY 98-99).
MAPS spent $5,348 on preliminary expenses for the MAPS-sponsored conference on
clinical research with MDMA and MDE, which took place in Israel at the Dead Sea on
Sept 1. This conference represents a major component in MAPS' efforts to obtain
MDMA psychotherapy research in Israel, Spain, the U.S. and elsewhere. Funds for this
were donated by Jeremy Tarcher, Robert Barnhart, Tim Butcher and Ami Shinitzky. A
this conference is in this issue, on page 2.
MAPS allocated $9,966 to the Elders conference in FY 98-99. This conference
in gathering together many early pioneers of psychedelic research where they could
reflect on the
insights gained from their research, both personal and as experimental subjects, and
strategize on ways to move forward with psychedelic research. MAPS brought Albert
Juraj and Sonja Styk, Swiss psychiatrists involved with psychedelic research and
Switzerland, to the conference, and assisted with additional expenses. Funds for this
were donated to MAPS by Tim Butcher and the Institute of Noetic Sciences.
In order for organizational expenses (salaries, Bulletins, phone, rent, etc.) to be met by
membership fees alone and not also by special donations, MAPS needs to increase its
to 2,500. The standard methods to build membership are by bulk mail solicitation or
MAPS, in collaboration with HRI, spent $3,789 in FY 98-99 as the last installment of a
mail campaign that was a dismal failure. About 55,000 letters were sent out to a variety of
we felt would be more inclined to be sympathetic to research. The only list for which we
the target of a 1% response rate was from the smallest-sized list. As a result of this
decided to abandon a shared direct mail campaign with MAPS.
MAPS redesigned the direct mail piece with the advice of professional consultants and
spent $9,158 on a subsequent campaign seeking membership only in MAPS. This campaign,
while more effective than the previous, still did not obtain the level of response required
the continuation of this effort. After MAPS succeeds in obtaining FDA permission for
psychotherapy research in the United States, research which has not taken place for over
years, it may prove easier to motivate people to support MAPS and the projects for which it
managed to obtain approval.
Our difficulties in obtaining new members means that current MAPS members are a
and unusual group! We need to do our best to ensure that a very high proportion of current
members decide to renew each year. MAPS also requests that each MAPS member consider
just one friend to also join MAPS. If you have any comments or suggestions that you would
willing to share with us about any aspect of MAPS, we would deeply appreciate hearing
MAPS spent $1,787 on internet functions including connection fees for staff and costs
the MAPS Forum and web site, with secure credit card processing. The MAPS web site has
very important educational tool and a source of contacts from new members, major funders
researchers. The site has received over 100,000 hits since November 1998. The server
donated and administered by Jim Petersen of San Francisco. Content is supervised and
Sylvia Thyssen and Andrew Stone. The web site underwent a major remodeling in March
thanks to Andew Stone of Stone Design. If you haven't already checked it out, I think you
probably like what you see, at www.maps.org.
MAPS allocated $116,459 to staff in FY 98-99. Of the amount, $100,134 went for
salaries, taxes and health care benefits, while $9,855 went for travel, $2,756 for
and $3,712 for professional fees such as accounting. MAPS has three full-time staff
Doblin, Sylvia Thyssen and Carla Higdon. We would like our compensation policy to enable
MAPS to retain its staff for may years to come, especially since, in my opinion, we all
qualified as time goes by. This is partially a result of the growth and development in our
contacts with researchers and members, thereby enhancing MAPS' ability to serve as one
the psychedelic community. It is also due to our growing understanding of the worldwide
psychedelic research projects, research design, and the regulatory approval process.
In FY 98-99, Rick Doblin's salary remained at $30,000 a year with no health care
Sylvia Thyssen received $28,600 with full health care benefits and Carla Higdon received
$22,880 with full health care benefits. In recognition of the long-term nature of MAPS'
and the excellent job done by both Sylvia and Carla, MAPS also makes contributions to a
retirement fund for them. These salaries and benefits are under market value for jobs in
private sector with similar responsibilities and required skills. For FY 99-2000, Rick
salary remains the same, Sylvia's salary was raised to $32,600 and Carla's salary was
MAPS allocated $14,298 to office expenses in FY 98-99. Of that amount, $3,966 went
rent. MAPS moved its location from Charlotte, North Carolina to Sarasota, Florida, and
$2,980 in moving expenses. $3,923 went for the purchase of a car to be used by MAPS staff
MAPS-related errands. The purchase of this car was largely paid for by restricted
Scientifically, FY 98-99 was a year in which several groundbreaking studies were
conducted, most notably Dr. Krupitsky's study of the use of ketamine-assisted
psychotherapy in the
treatment of heroin addicts, and the UC San Francisco study of Dr. Donald Abrams, in
effects of marijuana in HIV patients is being evaluated. A fascinating study of Salvia
and meditation was started, and a medical marijuana potency study was completed, both at
financial cost. A follow-up study to the LSD research of Dr. Janiger was completed and a
study to the LSD research of Dr. Bastiaans was initiated.
A great deal of energy was spent trying to obtain permission for MDMA research
around the world, for Dr. Russo's marijuana/migraine study in the United States, and for
application to have marijuana declared on Orphan Drug for AIDS wasting syndrome. The
of this effort can be seen in the FDA's final approval of Dr. Russo's study, which took
place in FY
99-2000, and FDA approval of MAPS' application to have marijuana declared an Orphan
for AIDS wasting syndrome, which also took place in FY 99-2000.
MAPS' work on behalf of MDMA research can be measured by whether approvals will be
granted in FY 99-2000 for MDMA psychotherapy projects in the United States, Israel and
Educationally, MAPS reached out to more people than ever through its Bulletin, various
web site projects, e-mail discussion group, book publication efforts, and membership
supported the Psychedelic Elders conference and began planning a major international
conference on the clinical use of MDMA.
Financially, MAPS raised a substantial amount of money that enabled it to support a
range of projects. MAPS' net assets were $351,701 as of May 31, 1999. Of these assets,
are restricted to specific research and educational projects and need to be subtracted from
assets when considering MAPS' unrestricted funds available for new projects or
expenses. These restricted sums will probably all be allocated in FY 99-2000.
MAPS' work load and range of projects increased, and with it the need to increase the
amount of unrestricted donations that MAPS can use for organizational expenses. The
disappointing results of the direct mail membership campaign means that MAPS needs to
its current members to remain supportive and to assist MAPS staff in outreach efforts to
new people who share MAPS' vision and goals and are willing to become formally involved
new MAPS members. Current MAPS members are an unusual group of people willing to
efforts to make this vision of the beneficial uses of psychedelics and marijuana into a
MAPS succeeds in obtaining FDA permission for psychedelic psychotherapy research in
United States, research which has not taken place for over 25 years, it may prove easier to
motivate people to support MAPS and the projects for which it has managed to obtain
This past year has been one of significant accomplishments, among the most important
being the building of a more mutually satisfactory working relationship with the FDA. I
expect that FY 99-2000 will see a continued improvement in MAPS' relationship with
bodies around the world.
Comments or questions from MAPS members concerning this annual report are invited.
Only with the continued support of its members can MAPS build in FY 99-2000 on the
expended since MAPS was founded in 1986. MAPS is deeply grateful for the past
MAPS' membership. We will do our best to be worthy of your renewed support.